A Medical Device Daily

Del Global Technologies (Valhalla, New York) issued a statement saying that it has concluded a review of its alternatives and has determined that "shareholders' interests will be best served by continuing to operate as a stand-alone strategy."

The company previously announced that it was unable to reach a definitive agreement with the party with whom it had entered into a non-binding letter of intent for the sale of its Medical Systems Group segment.

Since initiating the review of strategic alternatives, the company said it has completed the sale of its Del High Voltage division, reached a global settlement of the Department of Defense (DoD) investigation of its RFI subsidiary and is working with the Defense Logistics Agency, a component of the DoD, to avoid "any future limitations" on its ability to do business with entities of the U.S. government. In addition, it reported a return to profitability.

Thus, it has decided to remain independent.

"The board believes that tightening focus to continue to achieve profitability while operating on a stand-alone basis will ultimately generate superior shareholder value over the other options available to the company at this time," said Suzanne Hopgood, chairman of Del Global's board.

Del Global manufactures medical imaging and diagnostic technologies consisting of stationary and portable X-ray systems, radiographic/fluoroscopic systems, dental imaging systems and proprietary high-voltage power conversion subsystems for medical and other critical industrial applications.

Through its RFI subsidiary, it makes electronic filters, high-voltage capacitors, pulse modulators, transformers and reactors, and a variety of other products designed for industrial, medical, military and other commercial applications.